Development of an isotoxic decision support system integrating genetic markers of toxicity for the implantation of a rectum spacer

References

• Kalbasi A, Li J, Berman A, et al. Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncol. 2015;1:897–906.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Pei X, Chou JF, et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol. 2011;60:1133–1139.
   PubMed Web of Science ®Google Scholar
• Glass AS, Cowan JE, Fuldeore MJ, et al. Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology. 2013;82:60–65.
   PubMed Web of Science ®Google Scholar
• Vanneste BG, Van De Voorde L, de Ridder RJ, et al. Chronic radiation proctitis: tricks to prevent and treat. Int J Colorectal Dis. 2015;30:1293–1303.
   PubMed Web of Science ®Google Scholar
• Vanneste BG, Hoffmann AL, van Lin EN, et al. Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? A model-based approach for patient selection. Radiother Oncol. 2016;121:118–123.
   PubMed Web of Science ®Google Scholar
• Gez E, Cytron S, Ben Yosef R, et al. Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study. Radiat Oncol. 2013;8:96.
   PubMed Web of Science ®Google Scholar
• Pinkawa M, Corral NE, Caffaro M, et al. Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol. 2011;100:436–441.
   PubMed Web of Science ®Google Scholar
• Vanneste BG, van De Beek K, Lutgens L, et al. Implantation of a biodegradable rectum balloon implant: tips, tricks and pitfalls. Int Braz J Urol. 2017;43:1033.
   PubMed Web of Science ®Google Scholar
• Vanneste BGL, van Wijk Y, Lutgens LC, et al. Dynamics of rectal balloon implant shrinkage in prostate VMAT: Influence on anorectal dose and late rectal complication risk. Strahlenther Onkol. 2018;194:31–40.
   PubMed Web of Science ®Google Scholar
• Fachal L, Gomez-Caamano A, Barnett GC, et al. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nat Genet. 2014;46:891–894.
   PubMed Web of Science ®Google Scholar
• Kerns SL, Dorling L, Fachal L, et al. Meta-analysis of genome wide association studies identifies genetic markers of late toxicity following radiotherapy for prostate cancer. EBioMedicine. 2016;10:150–163.
   PubMed Web of Science ®Google Scholar
• Zindler JD, Thomas CR Jr., Hahn SM, et al. Increasing the therapeutic ratio of stereotactic ablative radiotherapy by individualized isotoxic dose prescription. JNCIJ. 2016;108:djv305.
   PubMedGoogle Scholar
• De Ruysscher D, van Baardwijk A, Steevens J, et al. Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study. Radiother Oncol. 2012;102:228–233.
   PubMed Web of Science ®Google Scholar
• Bongers ML, de Ruysscher D, Oberije C, et al. Model-based cost-effectiveness of conventional and innovative chemo-radiation in lung cancer. Int J Technol Assess Health Care. 2017;33:681–690.
   PubMed Web of Science ®Google Scholar
• van Wijk Y, Vanneste BGL, Walsh S, et al. Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: Comparison of dose, toxicity and cost-effectiveness. Radiother Oncol. 2017;125:107–112.
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–1430.
   PubMed Web of Science ®Google Scholar
• Withers HR, Thames HD, Jr, Peters LJ. A new isoeffect curve for change in dose per fraction. Radiother Oncol. 1983;1:187–191.
   PubMedGoogle Scholar
• Marzi S, Saracino B, Petrongari MG, et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res. 2009;28:117.
   PubMed Web of Science ®Google Scholar
• Michalski JM, Gay H, Jackson A, et al. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 2010;76:S123–S129.
   PubMed Web of Science ®Google Scholar
• Appelt AL, Vogelius IR. A method to adjust radiation dose-response relationships for clinical risk factors. Radiother Oncol. 2012;102:352–354.
   PubMed Web of Science ®Google Scholar
• Walsh S, van der Putten W. A TCP model for external beam treatment of intermediate-risk prostate cancer. Med Phys. 2013;40:031709.
   PubMed Web of Science ®Google Scholar
• Stewart RD, Li XA. BGRT: biologically guided radiation therapy-the future is fast approaching!. Med Phys. 2007;34:3739–3751.
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–974.
   PubMed Web of Science ®Google Scholar
• Viswanathan AN, Yorke ED, Marks LB, et al. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys. 2010;76:S116–S122.
   PubMed Web of Science ®Google Scholar
• Lambin P, van Stiphout RG, Starmans MH, et al. Predicting outcomes in radiation oncology–multifactorial decision support systems. Nat Rev Clin Oncol. 2013;10:27–40.
   PubMed Web of Science ®Google Scholar
• Chetty IJ, Martel MK, Jaffray DA, et al. Technology for innovation in radiation oncology. Int J Radiat Oncol Biol Phys. 2015;93:485–492.
   PubMedGoogle Scholar
• Lambin P, Zindler J, Vanneste B, et al. Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine. Acta Oncol. 2015;54:1289–1300.
   PubMed Web of Science ®Google Scholar
• Lambin P, Roelofs E, Reymen B, et al. 'Rapid Learning health care in oncology' – an approach towards decision support systems enabling customised radiotherapy'. Radiother Oncol. 2013;109:159–164.
   PubMed Web of Science ®Google Scholar
• Reymen B, van Baardwijk A, Wanders R, et al. Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR). Radiother Oncol. 2014;110:482–487.
   PubMed Web of Science ®Google Scholar
• Hoogeman MS, van Herk M, de Bois J, et al. Strategies to reduce the systematic error due to tumor and rectum motion in radiotherapy of prostate cancer. Radiother Oncol. 2005;74:177–185.
   PubMed Web of Science ®Google Scholar
• Pinkawa M, Klotz J, Djukic V, et al. Learning curve in the application of a hydrogel spacer to protect the rectal wall during radiotherapy of localized prostate cancer. Urology. 2013;82:963–968.
   PubMed Web of Science ®Google Scholar
• Lambin P, Zindler J, Vanneste BG, et al. Decision support systems for personalized and participative radiation oncology. Adv Drug Deliv Rev. 2017;109:131–153.
   PubMed Web of Science ®Google Scholar
• Vanneste BG, Pijls-Johannesma M, Van De Voorde L, et al. Spacers in radiotherapy treatment of prostate cancer: is reduction of toxicity cost-effective? Radiother Oncol. 2015;114:276–281.
   PubMed Web of Science ®Google Scholar